Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 12
Submit an article Journal homepage
357
Views
1
CrossRef citations to date
0
Altmetric
Review

Intelligent Design of Multifunctional lipid-coated Nanoparticle Platforms for Cancer Therapy

Srinivas Ramishettia Division of Molecular Pharmaceutics & Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel HillNC27599USA
&
Leaf Huangb Division of Molecular Pharmaceutics & Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel [email protected]
Pages 1429-1445 | Published online: 04 Dec 2012

References

  • Sinha R , KimGJ, NieS, ShinDM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther.5(8), 1909–1917 (2006).
  • Jabr-Milane LS , Van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev.34(7), 592–602 (2008).
  • Chaffer CL , WeinbergRA. A perspective on cancer cell metastasis. Science331(6024), 1559–1564 (2011).
  • Marshall E . Cancer research and the $90 billion metaphor. Science331(6024), 1540–1541 (2011).
  • Zhang L , GuFX, ChanJM, WangAZ, LangerRS, FarokhzadOC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther.83(5), 761–769 (2008).
  • Kim BY , RutkaJT, ChanWC. Nanomedicine. N. Engl. J. Med.363(25), 2434–2443 (2010).
  • Buse J , El-AneedA. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine (Lond.)5(8), 1237–1260 (2010).
  • Yu MK , ParkJ, JonS. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics2(1), 3–44 (2012).
  • Farrell D , PtakK, PanaroNJ, GrodzinskiP. Nanotechnology-based cancer therapeutics – promise and challenge – lessons learned through the NCI alliance for nanotechnology in cancer. Pharm. Res.28(2), 273–278 (2011).
  • Riehemann K , SchneiderSW, LugerTA, GodinB, FerrariM, FuchsH. Nanomedicine – challenge and perspectives. Angew. Chem. Int. Ed. Engl.48(5), 872–897 (2009).
  • Sokolova V , EppleM. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew. Chem. Int. Ed. Engl.47(8), 1382–1395 (2008).
  • Gratton SE , RoppPA, PohlhausPDet al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105(33), 11613–11618 (2008).
  • Decuzzi P , PasqualiniR, ArapW, FerrariM. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res.26(1), 235–243 (2009).
  • Champion JA , MitragotriS. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res.26(1), 244–249 (2009).
  • Smith BR , KempenP, BouleyDet al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Letts 12(7), 3369–3377 (2012)
  • Davis ME , ChenZG, ShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug. Discov.7(9), 771–782 (2008).
  • Alexis F , PridgenE, MolnarLK, FarokhzadOC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm.5(4), 505–515 (2008).
  • Longmire M , ChoykePL, KobayashiH. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.)3(5), 703–717 (2008).
  • Klibanov AL , MaruyamaK, TorchilinVP, HuangL. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett.268(1), 235–237 (1990).
  • Barreto JA , O‘MalleyW, KubeilM, GrahamB, StephanH, SpicciaL. Nanomaterials: applications in cancer imaging and therapy. Adv. Mater.23(12), 18–40 (2011).
  • Geng Y , DalhaimerP, CaiSet al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249–255 (2007).
  • Champion JA , MitragotriS. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA103(13), 4930–4934 (2006).
  • Decuzzi P , GodinB, TanakaTet al. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141(3), 320–327 (2010).
  • Schipper ML , IyerG, KohALet al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5(1), 126–134 (2009).
  • Bartlett DW , DavisME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem.18(2), 456–468 (2007).
  • Lee H , LeeK, ParkTG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug. Chem.19(6), 1319–1325 (2008).
  • Bartneck M , KeulHA, WambachMet al. Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. Nanomedicine doi:10.1016/j.nano.2012.02.012 (2012) (Epub ahead of print).
  • Xiao K , LiY, LuoJet al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32(13), 3435–3446 (2011).
  • Juliano RL , StampD. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun.63(3), 651–658 (1975).
  • Aggarwal P , HallJB, MclelandCB, DobrovolskaiaMA, McneilSE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev.61(6), 428–437 (2009).
  • Allen TM , HansenC. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta.1068(2), 133–141 (1991).
  • Malam Y , LoizidouM, SeifalianAM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci.30(11), 592–599 (2009).
  • Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Cancer307(1), 93–102 (2006).
  • Choi HS , IpeBI, MisraP, LeeJH, BawendiMG, FrangioniJV. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Letts9(6), 2354–2359 (2009).
  • Kaminskas LM , BoydBJ, KarellasPet al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers. Mol. Pharm. 5(3), 449–463 (2008).
  • Peracchia MT , FattalE, DesmaeleDet al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60(1), 121–128 (1999).
  • Zamboni WC . Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin. Cancer Res.11(23), 8230–8234 (2005).
  • Petros RA , DesimoneJM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug. Discov.9(8), 615–627 (2010).
  • Nakamura T , AkitaH, YamadaY, HatakeyamaH, HarashimaH. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc. Chem. Res.45(7), 1113–1121 (2012).
  • Wang T , UpponiJR, TorchilinVP. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Cancer427(1), 3–20 (2012).
  • Hatakeyama H , AkitaH, KogureKet al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14(1), 68–77 (2007).
  • Romberg B , HenninkWE, StormG. Sheddable coatings for long-circulating nanoparticles. Pharm. Res.25(1), 55–71 (2008).
  • Ishida T , MaedaR, IchiharaM, IrimuraK, KiwadaH. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release88(1), 35–42 (2003).
  • Ishida T , KiwadaH. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Cancer354(1–2), 56–62 (2008).
  • Ishihara T , TakedaM, SakamotoHet al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 26(10), 2270–2279 (2009).
  • Xu H , WangKQ, DengYH, Chen Da W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials31(17), 4757–4763 (2010).
  • Takeuchi H , KojimaH, YamamotoH, KawashimaY. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Control. Release75(1–2), 83–91 (2001).
  • Torchilin VP , LevchenkoTS, WhitemanKRet al. Amphiphilic poly-N-vinylpyrrolidones. synthesis, properties and liposome surface modification. Biomaterials 22(22), 3035–3044 (2001).
  • Whiteman KR , SubrV, UlbrichK, TorchilinVP. Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice. J. Liposome Res.11(2–3), 153–164 (2001).
  • Metselaar JM , BruinP, De Boer LW et al. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug. Chem.14(6), 1156–1164 (2003).
  • Fang J , NakamuraH, MaedaH. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63(3), 136–151 (2011).
  • Yuan F , LeunigM, HuangSK, BerkDA, PapahadjopoulosD, JainRK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res.54(13), 3352–3356 (1994).
  • Peer D , KarpJM, HongS, FarokhzadOC, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12), 751–760 (2007).
  • Allen TM , CullisPR. Drug delivery systems: entering the mainstream. Science303(5665), 1818–1822 (2004).
  • Hobbs SK , MonskyWL, YuanFet al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607–4612 (1998).
  • Heldin CH , RubinK, PietrasK, OstmanA. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer4(10), 806–813 (2004).
  • Farokhzad OC , LangerR. Impact of nanotechnology on drug delivery. ACS Nano.3(1), 16–20 (2009).
  • Gottesman MM , FojoT, BatesSE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer2(1), 48–58 (2002).
  • Kirpotin DB , DrummondDC, ShaoYet al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732–6740 (2006).
  • Van Rooy I , MastrobattistaE, StormG, HenninkWE, SchiffelersRM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control. Release150(1), 30–36 (2011).
  • Kwon IK , LeeSC, HanB, ParkK. Analysis on the current status of targeted drug delivery to tumors. J. Control. Release doi:10.1016/j.jconrel.2012.07.010 (2012) (Epub ahead of print).
  • Shi J , XiaoZ, KamalyN, FarokhzadOC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res.44(10), 1123–1134 (2011).
  • Kirpotin D , ParkJW, HongKet al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36(1), 66–75 (1997).
  • Bangham AD , HorneRW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol.8, 660–668 (1964).
  • Srinivas R , SamantaS, ChaudhuriA. Cationic amphiphiles: promising carriers of genetic materials in gene therapy. Chem. Soc. Rev.38(12), 3326–3338 (2009).
  • Torchilin VP . Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.4(2), 145–160 (2005).
  • Puri A , LoomisK, SmithBet al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26(6), 523–580 (2009).
  • Ramishetti S , ArupG, GopikrishnaM, SachinBA, ChaudhuriA. A long-lasting dendritic cell DNA vaccination system using lysinylated amphiphiles with mannose-mimicking head-groups. Biomaterials33(26), 6220–6229 (2012).
  • Vasievich EA , RamishettiS, ZhangY, HuangL. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol. Pharm.9(2), 261–268 (2012).
  • Un K , KawakamiS, SuzukiR, MaruyamaK, YamashitaF, HashidaM. Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials31(30), 7813–7826 (2010).
  • Stover TC , SharmaA, RobertsonGP, KesterM. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res.11(9), 3465–3474 (2005).
  • Goncalves A , BraudAC, ViretFet al. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res. 23(4), 3543–3548 (2003).
  • Schwonzen M , KurbacherCM, MallmannP. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs11(9), 681–685 (2000).
  • Shapiro EM , SkrticS, SharerK, HillJM, DunbarCE, KoretskyAP. MRI detection of single particles for cellular imaging. Proc. Natl Acad. Sci. USA101(30), 10901–10906 (2004).
  • Bulte JW , ZhangS, Van Gelderen P et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc. Natl Acad. Sci. USA96(26), 15256–15261 (1999).
  • Wilhelm C , FortinJP, GazeauF. Tumour cell toxicity of intracellular hyperthermia mediated by magnetic nanoparticles. J. Nanosci. Nanotechnol.7(8), 2933–2937 (2007).
  • Lin BL , ShenXD, CuiS. Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties. Biomed. Mater.2(2), 132–134 (2007).
  • Sun C , LeeJS, ZhangM. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev.60(11), 1252–1265 (2008).
  • Bhattarai SR , KimSY, JangKYet al. N-hexanoyl chitosan-stabilized magnetic nanoparticles: enhancement of adenoviral-mediated gene expression both in vitro and in vivo. Nanomedicine4(2), 146–154 (2008).
  • Plank C , SchillingerU, SchererFet al. The magnetofection method: using magnetic force to enhance gene delivery. Biol. Chem. 384(5), 737–747 (2003).
  • De Cuyper M , JoniauM. Magnetoliposomes. Formation and structural characterization. Eur. Biophys. J.15(5), 311–319 (1988).
  • Cesur H , RubinsteinI, PaiA, OnyukselH. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine5(2), 178–183 (2009).
  • Sabate R , Barnadas-RodriguezR, Callejas-FernandezJ, Hidalgo-AlvarezR, EstelrichJ. Preparation and characterization of extruded magnetoliposomes. Int. J. Cancer347(1–2), 156–162 (2008).
  • Martina MS , FortinJP, MenagerCet al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc. 127(30), 10676–10685 (2005).
  • Janib SM , MosesAS, MackayJA. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev.62(11), 1052–1063 (2010).
  • Zhang Y , KohlerN, ZhangM. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials23(7), 1553–1561 (2002).
  • Tai LA , TsaiPJ, WangYC, WangYJ, LoLW, YangCS. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology20(13), 135101 (2009).
  • Chen Y , BoseA, BothunGD. Controlled release from bilayer-decorated magnetoliposomes via electromagnetic heating. ACS nano.4(6), 3215–3221 (2010).
  • Pradhan P , GiriJ, RiekenFet al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J. Control. Release 142(1), 108–121 (2010).
  • Yang X , GrailerJJ, RowlandIJet al. Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging. Biomaterials 31(34), 9065–9073 (2010).
  • Wang H , WangS, LiaoZet al. Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. Int. J. Cancer 430(1–2), 342–349 (2012).
  • Fattahi H , LaurentS, LiuF, ArsalaniN, Vander Elst L, Muller RN. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond.)6(3), 529–544 (2011).
  • Felgner PL , TsaiYJ, SukhuLet al. Improved cationic lipid formulations for in vivo gene therapy. Ann. N. Y. Acad. Sci. 772, 126–139 (1995).
  • Gustafsson J , ArvidsonG, KarlssonG, AlmgrenM. Complexes between cationic liposomes and DNA visualized by cryo-TEM. Biochim. Biophys. Acta.1235(2), 305–312 (1995).
  • Li S , RizzoMA, BhattacharyaS, HuangL. Characterization of cationic lipid–protamine–DNA (LPD) complexes for intravenous gene delivery. Gene Ther.5(7), 930–937 (1998).
  • Li S , HuangL. In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes. Gene Ther.4(9), 891–900 (1997).
  • Li B , LiS, TanYet al. Lyophilization of cationic lipid–protamine–DNA (LPD) complexes. J. Pharm. Sci. 89(3), 355–364 (2000).
  • Gao X , HuangL. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry35(3), 1027–1036 (1996).
  • Li SD , HuangL. Surface-modified LPD nanoparticles for tumor targeting. Ann. N. Y. Acad. Sci.1082, 1–8 (2006).
  • Li SD , HuangL. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta.1788(10), 2259–2266 (2009).
  • Li SD , HuangL. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release145(3), 178–181 (2010).
  • Megalizzi V , Le Mercier M, Decaestecker C. Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy. Med. Res. Rev.32(2), 410–427 (2012).
  • Banerjee R , TyagiP, LiS, HuangL. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer112(4), 693–700 (2004).
  • John CS , VilnerBJ, GeyerBC, MoodyT, BowenWD. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res.59(18), 4578–4583 (1999).
  • John CS , BowenWD, FisherSJet al. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1´-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl. Med. Biol. 26(4), 377–382 (1999).
  • Li SD , ChonoS, HuangL. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control. Release126(1), 77–84 (2008).
  • Li SD , ChenYC, HackettMJ, HuangL. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther.16(1), 163–169 (2008).
  • Chen Y , BathulaSR, YangQ, HuangL. Targeted nanoparticles deliver siRNA to melanoma. J. Invest. Dermatol.130(12), 2790–2798 (2010).
  • Chen Y , BathulaSR, LiJ, HuangL. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem.285(29), 22639–22650 (2010).
  • Chen Y , ZhuX, ZhangX, LiuB, HuangL. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther.18(9), 1650–1656 (2010).
  • Johnson FM , SaigalB, TranH, DonatoNJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res.13(14), 4233–4244 (2007).
  • Kloth MT , LaughlinKK, BiscardiJS, BoernerJL, ParsonsSJ, SilvaCM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J. Biol. Chem.278(3), 1671–1679 (2003).
  • Shelburne CP , MccoyME, PiekorzRet al. Stat5 expression is critical for mast cell development and survival. Blood 102(4), 1290–1297 (2003).
  • Kim SK , HuangL. Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control. Release157(2), 279–286 (2012).
  • Hatakeyama H , AkitaH, HarashimaH. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev.63(3), 152–160 (2011).
  • Khalil IA , KogureK, FutakiS, HarashimaH. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem.281(6), 3544–3551 (2006).
  • El-Sayed A , KhalilIA, KogureK, FutakiS, HarashimaH. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J. Biol. Chem.283(34), 23450–23461 (2008).
  • Nakamura T , MoriguchiR, KogureK, ShastriN, HarashimaH. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol. Ther.16(8), 1507–1514 (2008).
  • Joraku A , HomhuanA, KawaiKet al. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guerin. BJU Int. 103(5), 686–693 (2009).
  • Li W , NicolF, SzokaFC Jr. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev.56(7), 967–985 (2004).
  • Hatakeyama H , ItoE, AkitaHet al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 139(2), 127–132 (2009).
  • Sakurai Y , HatakeyamaH, AkitaHet al. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Biol. Pharm. Bull. 32(5), 928–932 (2009).
  • Kakudo T , ChakiS, FutakiSet al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43(19), 5618–5628 (2004).
  • Subbarao NK , ParenteRA, SzokaFC Jr, Nadasdi L, Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry26(11), 2964–2972 (1987).
  • Sakurai Y , HatakeyamaH, SatoYet al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32(24), 5733–5742 (2011).
  • Trewyn BG , GiriS, Slowing, Ii, Lin VS. Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems. Chem. Commun. (Camb.) (31), 3236–3245 (2007).
  • Slowing II , TrewynBG, GiriS, LinVS. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Funct. Mater.17(8), 1225–1236 (2007).
  • Rosi NL , MirkinCA. Nanostructures in biodiagnostics. Chem. Rev.105(4), 1547–1562 (2005).
  • Jiang XM , BrinkerCJ. Aerosol-assisted self-assembly of single-crystal core/nanoporous shell particles as model controlled release capsules. J. Am. Chem. Soc.128(14), 4512–4513 (2006).
  • Cauda V , EngelkeH, SauerAet al. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Letts 10(7), 2484–2492 (2010).
  • Liu JW , Stace-NaughtonA, JiangXM, BrinkerCJ. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J. Am. Chem. Soc.131(4), 1354–1355 (2009).
  • Mal NK , FujiwaraM, TanakaY. Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature421(6921), 350–353 (2003).
  • Angelos S , ChoiE, VogtleF, De Cola L, Zink JI. Photo-driven expulsion of molecules from mesostructured silica nanoparticles. J. Phys. Chem. C111(18), 6589–6592 (2007).
  • Lai CY , TrewynBG, JeftinijaDMet al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J. Am. Chem. Soc. 125(15), 4451–4459 (2003).
  • Bally M , BaileyK, SugiharaK, GrieshaberD, VorosJ, StadlerB. Liposome and lipid bilayer arrays towards biosensing applications. Small6(22), 2481–2497 (2010).
  • Ashley CE , CarnesEC, PhillipsGKet al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 10(5), 389–397 (2011).
  • Mornet S , LambertO, DuguetE, BrissonA. The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano Letts5(2), 281–285 (2005).
  • Liu J , JiangX, AshleyC, BrinkerCJ. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J. Am. Chem. Soc.131(22), 7567–7569 (2009).
  • Graham FL , Van Der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology52(2), 456–467 (1973).
  • Kataoka Y , KaK. Block Copolymer self-assembly into monodispersive nanoparticles with hybrid core of antisense DNA and calcium phosphate. Langmuir18(12), 4539–4543 (2002).
  • Maitra A . Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev. Mol. Diagn.5(6), 893–905 (2005).
  • Olton D , LiJ, WilsonMEet al. Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials 28(6), 1267–1279 (2007).
  • Kakizawa Y , FurukawaS, IshiiA, KataokaK. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J. Control. Release111(3), 368–370 (2006).
  • Tabakovic A , KesterM, AdairJH. Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.4(1), 96–112 (2012).
  • Li J , ChenYC, TsengYC, MozumdarS, HuangL. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release142(3), 416–421 (2010).
  • Morgan TT , MuddanaHS, AltinogluEIet al. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Letts 8(12), 4108–4115 (2008).
  • Faraji AH , WipfP. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem.17(8), 2950–2962 (2009).
  • Li J , YangY, HuangL. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release158(1), 108–114 (2012).
  • Yang Y , HuY, WangY, LiJ, LiuF, HuangL. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol. Pharm. doi:10.1021/mp300152v (2012) (Epub ahead of print).
  • Huang L , LiuY. In vivo delivery of RNAi with lipid-based nanoparticles. Annu. Rev. Biomed. Eng.13, 507–530 (2011).
  • Yang Y , LiJ, LiuF, HuangL. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther.20(3), 609–615 (2012).
  • Huynh NT , PassiraniC, SaulnierP, BenoitJP. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Cancer379(2), 201–209 (2009).
  • Coon JS , KnudsonW, ClodfelterK, LuB, WeinsteinRS. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res.51(3), 897–902 (1991).
  • Lamprecht A , BenoitJP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release112(2), 208–213 (2006).
  • Garcion E , LamprechtA, HeurtaultBet al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5(7), 1710–1722 (2006).
  • Morille M , PassiraniC, DufortSet al. Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials 32(9), 2327–2333 (2011).
  • Vonarbourg A , PassiraniC, DesigauxLet al. The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials 30(18), 3197–3204 (2009).
  • Bhaumik S . Advances in imaging gene-directed enzyme prodrug therapy. Curr. Pharm. Biotechnol.12(4), 497–507 (2011).
  • David S , CarmoyN, ResnierPet al. In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int. J. Cancer423(1), 108–115 (2012).
  • Trickler WJ , MuntDJ, JainN, JoshiSS, DashAK. Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel. Nanomedicine (Lond.)6(3), 437–448 (2011).
  • Hasan W , ChuK, GullapalliAet al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Letts. 12(1), 287–292 (2012).
  • Li W , YangY, WangCet al. Carrier-free, functionalized drug nanoparticles for targeted drug delivery. Chem. Commun. (Camb.) 48(65), 8120–8122 (2012).
  • Khandare J , CalderonM, DagiaNM, HaagR. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem. Soc. Rev.41(7), 2824–2848 (2012).
  • Park JW , HongK, KirpotinDBet al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172–1181 (2002).
  • Sun B , RanganathanB, FengSS. Multifunctional poly(D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials29(4), 475–486 (2008).
  • Gao J , ZhongW, HeJet al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Cancer 374(1–2), 145–152 (2009).
  • Farokhzad OC , JonS, KhademhosseiniA, TranTN, LavanDA, LangerR. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res.64(21), 7668–7672 (2004).
  • Farokhzad OC , ChengJ, TeplyBAet al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315–6320 (2006).
  • Sahoo SK , LabhasetwarV. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm.2(5), 373–383 (2005).
  • Li JL , WangL, LiuXYet al. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett.274(2), 319–326 (2009).
  • Thomas TP , ShuklaR, KotlyarAet al. Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules 9(2), 603–609 (2008).
  • Karmali PP , KotamrajuVR, KastantinMet al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5(1), 73–82 (2009).
  • Sugahara KN , TeesaluT, KarmaliPPet al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031–1035 (2010).
  • Oh S , KimBJ, SinghNP, LaiH, SasakiT. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett.274(1), 33–39 (2009).
  • Lo A , LinCT, WuHC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther.7(3), 579–589 (2008).
  • Wang S , LowPS. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control. Release53(1–3), 39–48 (1998).
  • Zeng C , VangveravongS, XuJet al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 67(14), 6708–6716 (2007).
  • Hornick JR , XuJ, VangveravongSet al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. Cancer 9, 298 (2010).
  • Wang B , RouzierR, AlbarracinCTet al. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res. Treat. 87(3), 205–214 (2004).
  • Kim TH , ParkIK, NahJW, ChoiYJ, ChoCS. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials25(17), 3783–3792 (2004).
  • Ashley CE , CarnesEC, EplerKEet al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 6(3), 2174–2188 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.